MPM

NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List

Retrieved on: 
Lunedì, Maggio 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Public, Cancer, Doctor of Philosophy, MPM, TIME, Therapy, Patient, Medicine, Medicare, Drug development, Pharmaceutical industry

NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7/HHLA2 axis, announced today that Chief Executive Officer Ivan Cheung has been named to the 2024 TIME100 Health List.

Key Points: 
  • NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7/HHLA2 axis, announced today that Chief Executive Officer Ivan Cheung has been named to the 2024 TIME100 Health List.
  • The inaugural TIME100 Health list recognizes the 100 most influential individuals in health and medicine who have made significant contributions to improving global health outcomes, advancing medical research and driving innovation in healthcare delivery.
  • As a member of the TIME100 Health list, Mr. Cheung joins a distinguished group of individuals who are shaping the future of healthcare and driving positive change on a global scale.
  • The full list and related tributes appear in the May 13, 2024 issue of TIME and at time.com/time100health .

Generational Group Advises Wale Apparatus in its Sale to Private Investor

Retrieved on: 
Mercoledì, Maggio 1, 2024
Consulting, Automotive Manufacturing, Aerospace, Manufacturing, Professional Services, Other Science, Other Manufacturing, Engineering, Science, Finance, Chemicals, Plastics, Acquisition, Sale, Wale, M&A, Momentive, Glass, MPM

Generational Group , a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client Wale Apparatus Co. to a Private Investor.

Key Points: 
  • Generational Group , a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client Wale Apparatus Co. to a Private Investor.
  • Wale Apparatus (Wale), located in Hellertown, Pennsylvania, is a leading reseller of glass working equipment and supplies and fabrication of glass and quartz materials.
  • Generational Group Executive Managing Director, M&A-Technology Practice Leader, David Fergusson , and Generational Group Authorized Affiliate, Mark Shortz, with the support of Managing Director, M&A, Corey Painter successfully closed the transaction.
  • Senior Managing Director, Thomas Hamm established the initial relationship with Wale Apparatus.

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Retrieved on: 
Venerdì, Aprile 26, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, School, University, Global Oncology, Cancer, Wastewater treatment, University of Pennsylvania, Pharmacovigilance, Incyte, Hematology, GSK plc, Drug, Partnership, MPM, Senior, Patient, Therapy, Head

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.
  • “On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare into the leading precision oncology company that it is today.
  • "I look forward to the ongoing advancement of Repare’s pipeline and its continued progress as a leading precision oncology company."
  • Dr. Stein also previously served on the board of directors of Kura Oncology, Inc. from 2017 until May 2023.

MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner

Retrieved on: 
Giovedì, Aprile 11, 2024
University, Kite, Sanofi, Research, MD Anderson Cancer Center, MPM, History, Takeda Pharmaceutical Company, Heinrich Heine University Düsseldorf, Senior, Patient, Intellectual property, Internal medicine, Biotechnology, AstraZeneca, Verastem Oncology, Bluebird bio, Nursing

In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.

Key Points: 
  • In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.
  • "Frank is an innovator and distinguished leader with a demonstrated history of success in CAR-based cell therapy and clinical advancement," said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact.
  • Dr. Neumann's deep clinical experience will serve to support MPM BioImpact's investment process and the advancement of its underlying portfolio companies.
  • "I'm thrilled to join the MPM BioImpact ecosystem and contribute to its patient-focused mission," said Dr. Neumann.

Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Giovedì, Aprile 11, 2024
University, Sanofi, RNA, Research, MD Anderson Cancer Center, MPM, Takeda Pharmaceutical Company, Heinrich Heine University Düsseldorf, Therapy, Bone marrow, Partner (business rank), Senior, Patient, Internal medicine, Biotechnology, AstraZeneca, Verastem Oncology, Bluebird bio

WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer. In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.

Key Points: 
  • WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.
  • In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.
  • "We are delighted to welcome Frank, an accomplished leader with a proven track record in CAR-based cell therapy and clinical development," said Tom Barnes, Ph.D., Chief Executive Officer of Orna Therapeutics.
  • "Orna's truly innovative approach to RNA therapeutics shows incredible promise to fundamentally change the way life-threatening diseases are treated," said Dr. Neumann.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Martedì, Febbraio 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Firefly Bio Debuts With $94 Million Series A Financing

Retrieved on: 
Giovedì, Febbraio 15, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Versant, Merck, MPM, Nobel Prize, Collateral damage, Therapeutic index, Cell, Eli Lilly and Company, ADC, Genentech, Protein, Nobel Prize in Chemistry, Novartis, CSO, Firefly, FireLink, Cancer, Fine chemical

Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.

Key Points: 
  • Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
  • Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs).
  • Firefly was incubated in close collaboration with scientists at Versant’s Ridgeline Discovery Engine in the Basel Technology Park.
  • “At Firefly, we’ve assembled a unique talent base and platform to significantly advance this promising field,” said Jerel Davis, Ph.D., Managing Director at Versant and a Firefly board member.

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

Retrieved on: 
Mercoledì, Febbraio 14, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, MPM, Doctor of Philosophy, Immunotherapy, Extension, Dana–Farber Cancer Institute, Series, WTT, Bayer, Patient, Cancer, Pharmaceutical industry

NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing.

Key Points: 
  • NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing.
  • The Extension was led by existing investor Catalio Capital Management, and as part of the financing, R. Jacob Vogelstein, PhD, has joined the NextPoint Board of Directors.
  • Catalio is joined by other existing investors including MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Dana-Farber Cancer Institute’s Binney Street Capital and NextPoint founder Gordon Freeman, PhD.
  • Along with Catalio, new investors Arkin Bio-Capital and WTT investment Ltd were the largest participants in this fundraising.

NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer

Retrieved on: 
Giovedì, Febbraio 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Public, Growth, Booz Allen Hamilton, Harvard Business School, Therapy, Duke University, Patient, MBA, MPM, Drug development, PD-1, Doctor of Philosophy, Detlev, Cancer, Medicare, Pharmaceutical industry

NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Ivan Cheung as Chief Executive Officer (CEO) and to the Board of Directors.

Key Points: 
  • NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Ivan Cheung as Chief Executive Officer (CEO) and to the Board of Directors.
  • Mr. Cheung brings 25 years of drug development, approval and product launch achievements, and organizational leadership experience to NextPoint, most recently serving as Eisai’s U.S. CEO.
  • With his appointment, NextPoint aims to deliver breakthrough clinical outcomes from precision immuno-oncology therapeutics targeting the HHLA2 checkpoint axis and create additional modalities leveraging HHLA2 as a novel tumor antigen.
  • Under Dr. Biniszkiewicz’s leadership, NextPoint raised Series A and B funding and was transformed into a clinical-stage company.

AHN Allegheny General Hospital Achieves Prestigious Magnet® Designation for Nursing Excellence

Retrieved on: 
Venerdì, Gennaio 19, 2024
Magnet, AHN, Organ transplantation, General Hospital, Patient, Commission, Nursing, Allegheny General Hospital, Professional, Hospital, Trauma, MD, RN, BSN, Health, Culture, Medicine, Neuroscience, AGH, Allegheny Health Network, Doctor of Philosophy, Organization, MPM, ANCC, Research

PITTSBURGH, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.

Key Points: 
  • Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.
  • PITTSBURGH, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.
  • This Magnet designation is a reflection of the tireless dedication and exceptional nursing skills of our team at Allegheny General Hospital.
  • It is now the fourth AHN hospital to receive the Magnet designation, part of the network's ongoing campaign to transform the practice of nursing and sustain a culture of nursing excellence and innovation.